Jane Street
OTLK icon

Jane Street’s Outlook Therapeutics OTLK Stock Holding History

Jane Street’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75K Buy
23,100
+5,700
+33% +$2.46K ﹤0.01% 11357
2025
Q4 		$27.5K Buy
17,400
+2,900
+20% +$4.63K ﹤0.01% 10662
2025
Q3 		$15.4K Buy
+14,500
New +$25.1K ﹤0.01% 10558

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Jane Street's OTLK Position: Q1 2026 in Review

Jane Street sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 104,662 shares — an estimated $45.2K sold.

Jane Street first reported a position in OTLK in Q3 2019 and held it in 14 quarters. The position peaked at $165K in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Jane Street reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 104,662 Outlook Therapeutics shares in Q1 2026, an estimated $45.2K.
  • Jane Street first reported a position in Outlook Therapeutics in Q3 2019 and held it in 14 quarters.
  • Jane Street's Outlook Therapeutics position peaked at $165K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.